Conference Reports for NATAP

Back

ID Week Oct 19, -23 2022 Washington DC     Single-Tablet Regimens (STR) Offer Better Persistence and Adherence, With Lower Costs by Adherence Status, Than Multiple-Tablet Regimens (MTR) for People Living With HIV (PLWH) Enrolled in Medicaid - (11/02/22)   Screening for Hepatitis C as Part of an Opioid Stewardship Initiative: Identifying Infected Patients and Analyzing Linkage to Care - (10/26/22)   A Step Toward Universal HCV Screening: Write a Letter - Mark Mascolini - (10/26/22)   A Case Series of Lo-Level HBV Viremia After Switching to Long-Acting Injectable Cabotegravir/Rilpivirine in Patients with HIV, Hepatitis B Core Antibody Positivity, and Hepatitis B Surface Antigen Negativity - - (10/26/22)   Switching to an Integrase Inhibitor Tied to Liver Fibrosis Score in US Women - Mark Mascolini - (10/25/22)   On-Demand and Long-Acting PrEP Both Stir Interest in US Survey of MSM - Mark Mascolini (10/25/22)   High PrEP Awareness in US Women, But Only 20% Ever Used It - Mark Mascolini (10/25/22)   B/F/TAF for 48 Weeks in US Group With Substance Use and Other Challenges - Mark Mascolini (10/25/22)   CAB + RPV LA in Europe: HIV Control in 87% With Standard or Enhanced Support - Mark Mascolini (10/25/22)   Ivermectin, Fluticasone, Fluvoxamine Can't Beat Placebo for Mild/Moderate COVID - Mark Mascolini (10/25/22)   Postacute COVID Less Common in US Youth Than Reported Earlier - Mark Mascolini (10/25/22)   Age, Immune Conditions, Comorbidities Drive Severe COVID Risk After Vaccination - Mark Mascolini (10/25/22)   In Big US HIV Group, Hispanics, Blacks, Southerners, Overweight Run Higher COVID Risk - Mark Mascolini (10/25/22)   Impaired Fitness Peaks 1 Month After COVID Onset but May Persist 12 Months - Mark Mascolini (10/25/22)   CAB + RPV LA in Europe: HIV Control in 87% With Standard or Enhanced Support - Mark Mascolini (10/24/22)   On-Demand and Long-Acting PrEP Both Stir Interest in US Survey of MSM - Mark Mascolini (10/24/22)   Phase 3/3b Experience With Long-Acting Cabotegravir and Rilpivirine: Efficacy and Safety Outcomes Through Week 96 by Race - (10/24/22)   B/F/TAF an Effective and Safe Switch for HIV/HBV: 24-Week Results - Mark Mascolini (10/24/22)   Lenacapavir: 75% Sub-50 Response at 52 Weeks Despite Heavy ART Experience - Mark Mascolini (10/24/22)   High Exposure to Antilipid Drugs Tied to Lower Mortality in Older HIV Group - Mark Mascolini (10/24/22)   Some "Excess Risk" of Delayed ART in START Trial Persists for Years - (10/24/22)   HIV, Dementia, Cognitive Concerns Tied to Death in COVID Patients - (10/24/22)   CARISEL: A Hybrid Type III Implementation Effectiveness Study of Implementation of Cabotegravir + Rilpivirine Long-Acting (CAB + RPV LA) in European Health Care Settings; Key Clinical and Implementation Outcomes by Implementation Arm - (10/24/22)   76% of PLWH >50 Report Suboptimal Health - Clinical and Sociodemographic Characteristics Associated With Poor Self-rated Health Across Multiple Domains Among Older North American Adults Living With HIV - (10/24/22)   Factors Associated with Viremia in Transgender Individuals Living with HIV - (10/24/22)   Real-World Use of Long-Acting Cabotegravir + Rilpivirine in the US: Effectiveness in the First Year - (10/24/22)   Update on PrEP Knowledge and Attitudes Among Adults Attending Public Health Clinics in Southern Arizona - (10/24/22)   Life-years Gained among non-Hispanic Black and White Men who have Sex with Men in the United States with Improvements in the HIV Care Continuum A Simulation Modeling Study - (10/24/22)   Relative patient preferences for starting daily, on-demand, and long-acting injectable HIV pre-exposure prophylaxis among US men who have sex with men, 2021-2022 - (10/24/22)   Hepatitis D Virus and Hepatitis B Virus Epidemiology in Utah - (10/24/22)   HEPATITIS C CASCADE OF CARE IN A MULTIDISCIPLINARY SUBSTANCE USE BRIDGE CLINIC MODEL - (10/23/22)   Hepatitis C Treatment as a Complement to Syringe Service Programs: Pilot Progress and Pathways Forward - (10/23/22)   Analysis of an Automated Letter HCV Screening Program within a Veterans Affairs Health System: Implications for Universal HCV Screening - (10/23/22)   Screening for Hepatitis C as Part of an Opioid Stewardship Initiative: Identifying Infected Patients and Analyzing Linkage to Care - (10/23/22)   PrEP Awareness and Use among Reproductive Age Women in Miami, Florida - (10/23/22)   PrEP Interest and Preferences Among US Black and Hispanic Men - A 2021 National Survey - (10/23/22)   Systematic Literature Review of Real-world Experience With the 2-Drug Regimen Dolutegravir and Lamivudine in People With HIV Who Would Not Have Met Inclusion Criteria for the Phase 3 Clinical Program - (10/23/22)   Awareness and Interest in PrEP Options Among US Cisgender Women - A National Survey - (10/23/22)   High PrEP Awareness in US Women, But Only 20% Ever Used It - Mark Mascolini (10/23/22)   A Real-World Observational Study on Patients With HIV Who Switched From Nevirapine + 2 Nucleoside Reverse Transcriptase Inhibitors to Dolutegravir/Lamivudine in British Columbia, Canada - (10/23/22)   Durability and effectiveness of fostemsavir in heavily treatment-experienced people with HIV - (10/23/22)   Effectiveness and Durability of Dolutegravir (DTG) Based Regimens in Older People Living With HIV (PLWH) From the Veterans Aging Cohort Study (VACS) - (10/23/22)   Real-world Treatment Experience of Single-tablet Dolutegravir/Lamivudine in those Naïve to Treatment with Baseline Viral Loads ≥100,000 copies/mL the United States - (10/23/22)   Suppressed Switch to DTG/3TC 2-Drug Regimen Vs. BIC- or DTG-Based 3-Drug Regimens - (10/23/22)   Efficacy and Safety of Long-Acting Subcutaneous Lenacapavir in Heavily Treatment-Experienced People With Multi-Drug Resistant HIV: Week 52 Results - (10/23/22)   Safety, Tolerability, and Pharmacokinetics of BRII-778, A Modified-Release Oral Formulation of Rilpivirine in Healthy Adult Subjects - (10/23/22)   Safety, Tolerability, and Pharmacokinetics of BRII-732, A Medoxomil Carbonate Prodrug of Islatravir in Healthy Adult Subjects - (10/23/22)   Brii Biosciences Presents Promising Clinical Data to Support Ongoing Development of Novel HIV Therapeutic Candidates at IDWeek 2022 - (10/23/22)   Real-world Treatment Experience of Treatment-naïve People Living with HIV who Initiated Treatment with Single-tablet Dolutegravir/Lamivudine in a Test and Treat Setting in the United States - (10/23/22)   Real-world Geographic Variations of HIV Diagnosis Rates Among Individuals Prescribed and Not Prescribed Oral HIV Pre-Exposure Prophylaxis Regimens in the United States - (10/23/22)   Estimated Background HIV Diagnosis Rates Among People Who Could Benefit From Pre-Exposure Prophylaxis at the Metropolitan Statistical Area Level in the United States, 2012-2019 - (10/23/22)   Efficacy and Safety of Switching to DTG/3TC in Virologically Suppressed PLWH by Age, Including Those Aged ≥65 Years: Pooled Results From the TANGO and SALSA Studies - (10/23/22)   76% >50 PLWH Report Suboptimal Mental, Physical Health- Clinical and Sociodemographic Characteristics Associated With Poor Self-rated Health Across Multiple Domains Among Older North American Adults Living With HIV - (10/23/22)   5-Year Outcomes of Bictegravir/Emtricitabine/Tenofovir Alafenamide as Initial Treatment of HIV-1 in Adults With High Baseline HIV-1 RNA and/or Low CD4 Count in Two Phase 3 Randomized Clinical Trials - (10/23/22)